Faron Pharma expands bexmarilimab programme in solid tumours with a randomized phase I/II BEXAR IIT in metastatic soft-tissue sarcoma: Turku, Finland Thursday, January 29, 2026, 1 ...

Anlotinib combined with chemotherapy showed a 30.8% ORR and 82.7% DCR in advanced STS patients, indicating promising efficacy ...

The FDA's orphan drug designation supports LP-284's development for soft tissue sarcomas, addressing significant unmet needs in this adult patient population. The FDA granted orphan drug designation ...

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discovery and development, today ...

Combining immunotherapy with radiation could be a promising treatment option for patients with advanced soft tissue sarcoma, according to the results of a clinical trial led by Northwestern Medicine ...

Eftilagimod alfa and Keytruda with radiotherapy improved tumor hyalinization/fibrosis rates in resectable soft tissue sarcoma, surpassing the trial's primary endpoint. The combination therapy achieved ...

Prognostic factors in soft tissue sarcomas encompass a diverse spectrum of clinical, pathological and host-related parameters that influence patient outcomes. Increasingly, research is demonstrating ...

Despite such guidelines, though, the investigators said there is a lack of evidence-based or widely accepted consensus on ...

What at least one investigator has been saying for nearly 2 decades is supported by a new study: 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) can provide important prognostic ...

Canine soft tissue sarcomas (STS) constitute a heterogeneous group of mesenchymal tumours that present diverse morphological and clinical profiles. These neoplasms commonly affect the skin and ...

Study conducted in a collaboration between MEDSIR and University Hospital Vall d'Hebron to evaluate bexmarilimab plus standard-of-care doxorubicin in a high-unmet-need frontline setting. TURKU, FI / ...

Study conducted in a collaboration between MEDSIR and University Hospital Vall d'Hebron to evaluate bexmarilimab plus standard-of-care doxorubicin in a high-unmet-need frontline setting. TURKU, FI / A ...